Drugs / Expanded autologous adipose-derived adult stem cells (eASCs)
Expanded autologous adipose-derived adult stem cells (eASCs)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01378390 | Dec 2008 → Feb 2010 | Crohn disease, anal fistula | Tigenix S.A.U. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Expanded autologous adipose-derived adult stem cells (eASCs) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01378390 ↗ |
| Modality | Cell therapy | “eASCs (expanded adult stem cells)” NCT01378390 ↗ |
| Route | Other | “Intralesional dose of 20 million cells at baseline” NCT01378390 ↗ |